KCNA5 and atrial fibrillation: It has been shown to be effective in terminating acute-onset atrial fibrillation but is relatively nonspecific and can also have some inhibitory effects on Ito and IKr currents.136 Bristol-Myers Squibb has a KV1.5 inhibitor BMS-919373 in phase 1 trials to study the effects on atrial ERP in patients with a pacemaker (NCT02153437) and in phase 2 trials to assess the effect of BMS-919373 on the time spent in AF (NCT02156076).